Founder, Symbl.ai.(May 2018 - Till Now)
Surbhi is CEO and co-founder of Symbl.ai. Symbl is bringing to life her vision for a programmable platform that empowers developers and businesses to build unique conversational experiences without the hassle of upfront training or building their in-house data science expertise. She co-founded Symbl (previously Rammer.ai) almost 2 years ago and was a part of the Alexa Next Stage program by Techstars 2020. Symbl raised an early-stage venture round of 1.8M almost a year ago and deployed capital to grow a team of tech enthusiasts to 25 people primarily distributed between India and Seattle. She comes with experience from technical and customer-obsessed roles in both startups and enterprises such as Nevis Networks and Amdocs. Before co-founding Symbl, she worked in the Conversational AI space with a focus on delivering value to Telecommunication users. She is an advocate for Women in AI with a personal mission to inspire more women to work in Data Science. In her free time, she loves to travel and spend time with her remote and distributed family across continents.
Partner, Perkins Coie(Jan 2014 - Till Now)
Lee Schindler, a partner in the Emerging Companies & Venture Capital practice, serves as corporate counsel to high growth technology and life science companies. Lee also represents the venture capitalists and corporate venture groups that invest in such companies.
Lee regularly advises clients across a range of industries and technologies, including software-as-a-service, cloud infrastructure, mobile applications and gaming, AI and machine learning, data security, blockchain, fintech, e-commerce, UAVs, cleantech, material science, healthcare IT, medical devices and biotechnology. Many of the companies Lee works with have emanated from Massachusetts Institute of Technology, Harvard University, the University of Washington or other academic or research institutions.
Lee has counseled numerous companies from their earliest stages of growth through exit events, including several IPOs and dozens of M&A transactions. His representation corresponds to every critical point involving emerging companies and the VC community. This includes entity formation, board matters, securities law compliance, equity compensation, financings (friends & family, angel, venture capital, growth equity and strategic), mergers & acquisitions and public offerings. Lee also works closely with his clients on fundraising strategy.
Founding Partner, Fuse Venture Partner(July 2020 - Till Now)
Cameron founded Fuse in 2020 where he focuses on early stage investments in horizontal and vertical intelligent application software. Previously, Cameron was a Principal at Ignition Partners, a leading early stage venture capital firm. At Ignition, Cameron played a key role in sourcing, identifying, and supporting new investments including as a board observer on Maka. Cameron joined Ignition after several years working in technology investment banking and co-founding a seed stage investing firm, Curious Capital.
Prior to Ignition, Cameron was a co-founder of Curious Capital. He raised a small fund of outside capital to invest in innovative seed-stage technology companies based in the Pacific Northwest. Prior to Curious, Cameron was a technology investment banker at Vaquero Capital in San Francisco. At Vaquero, Cameron was critical in leading marketing and diligence efforts, as well as sourcing transactions for two leading software companies. Cameron also worked as a financial analyst intern for Isilon/EMC.
Cameron holds a BS degree in Business Administration-Finance from the Foster School of Business at the University of Washington.
Andrew J. Holman, MD.
CEO & Co-founder Inmedix, Inc.(Jan 2006 - Till Now)
Andrew J. Holman, MD is CEO & Co-founder of Seattle-based Inmedix, Inc., a Clinical Associate Professor of Medicine at the University of Washington and for 25 years, the primary clinical rheumatologist at Valley Medical Center in Renton, WA. Inmedix was created in 2006 to hold patents related to Dr. Holman's research, first resulting in a $10MM sale to Boehringer-Ingelheim Pharmaceuticals in 2007. Since then, Inmedix has applied additional IP to bring bloodless clinical diagnostics to medicine on its innovative cloud platform, beginning with accurate measurement of fight-or-flight stress to quantify and mitigate how stress drives diseases to excess, impairs therapeutic success and increases costs of care. This lead Inmedix diagnostic, the ANS Neuroscan, offers a reimbursed point-of-care diagnostic applying 5-min, next-generation heart rate variability (HRV) currently used in professional sports and US Special Forces for human performance training. The device/diagnostic/cloud platform is currently working its way through final engineering and FDA/CE clearance to be available to clinicians in late 2021.